Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Phase 1

Terminated

Conditions: Relapsed Central Nervous System Tumor
Diffuse Intrinsic Pontine Glioma
Refractory Central Nervous System Tumor
Relapsed Solid Tumor
High Grade Glioma
Refractory Solid Tumor

Interventions: Drug: cemiplimab (monotherapy)
Drug: cemiplimab (maintenance)
Radiation: Conventional or hypofractionated
Radiation: Re-irradiation

First Posted Date: 2018-10-01

Last Posted Date: 2025-04-08

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT03690869

Locations: 🇺🇸
Children's Hospital Los Angeles (CHLA), Los Angeles, California, United States
🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 17 locations

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Phase 2

Completed

Conditions: Peanut Allergy

Interventions: Drug: Placebo matching dupilumab
Drug: Dupilumab
Drug: AR101

First Posted Date: 2018-09-25

Last Posted Date: 2024-02-07

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 148

Registration Number: NCT03682770

Locations: 🇺🇸
Regeneron Investigational Site, Seattle, Washington, United States

Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: REGN5069
Drug: Placebo

First Posted Date: 2018-08-24

Last Posted Date: 2019-11-26

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT03645746

Locations: 🇧🇪
Regeneron Research Facility, Gent, Belgium

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

Phase 3

Completed

Conditions: Eosinophilic Esophagitis

Interventions: Drug: Dupilumab
Drug: Placebo

First Posted Date: 2018-08-16

Last Posted Date: 2023-06-28

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 321

Registration Number: NCT03633617

Locations: 🇬🇧
Regeneron Study Site, Barnsley, Yorkshire, United Kingdom
🇺🇸
Regeneron Study Site #2, Chicago, Illinois, United States
🇺🇸
Regeneron Study Site #1, Chicago, Illinois, United States

Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: REGN4659
Drug: Cemiplimab

First Posted Date: 2018-07-09

Last Posted Date: 2020-03-13

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT03580694

Locations: 🇺🇸
Regeneron Investigational Site, San Antonio, Texas, United States

R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease

Conditions: Ebola Virus Disease

First Posted Date: 2018-07-03

Last Posted Date: 2024-11-08

Lead Sponsor: Regeneron Pharmaceuticals

Registration Number: NCT03576690

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Phase 1

Recruiting

Conditions: Recurrent Primary Peritoneal Cancer
Recurrent Endometrial Cancer
Recurrent Ovarian Cancer
Recurrent Fallopian Tube Cancer

Interventions: Drug: REGN4018
Drug: Sarilumab
Drug: cemiplimab

First Posted Date: 2018-06-20

Last Posted Date: 2025-04-16

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 690

Registration Number: NCT03564340

Locations: 🇬🇧
Guys Hospital, London, United Kingdom
🇮🇱
Sharet Institute of Oncology, Jerusalem, Israel
🇺🇸
University of Alabama_6th Ave, Birmingham, Alabama, United States

and more 48 locations